Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Share-based Compensation (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Share-based Compensation for 11 consecutive years, with $33000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Share-based Compensation fell 37.74% to $33000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $476824.0, a 223.43% increase, with the full-year FY2024 number at $246000.0, down 71.34% from a year prior.
  • Share-based Compensation was $33000.0 for Q3 2025 at Marker Therapeutics, up from $14000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $1.7 million in Q2 2021 to a low of -$581731.0 in Q4 2023.
  • A 5-year average of $675805.2 and a median of $606000.0 in 2023 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: crashed 181.13% in 2023, then skyrocketed 377.41% in 2025.
  • Marker Therapeutics' Share-based Compensation stood at $1.5 million in 2021, then plummeted by 51.12% to $717000.0 in 2022, then plummeted by 181.13% to -$581731.0 in 2023, then skyrocketed by 108.71% to $50680.0 in 2024, then crashed by 34.89% to $33000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Share-based Compensation are $33000.0 (Q3 2025), $14000.0 (Q2 2025), and $379144.0 (Q1 2025).